Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-25

While it might be 'old news' as some are claiming ..... it certainly is relevant to the current phase 3 COVID-19 ARDS trial - just sayin'

It is the company IMO reaffirming that we have something to treat this awful illness, but hey short away if you still believe this information won't be replicated in the current phase 3 trial ... LMAO

Mesoblast Chief Medical Officer Dr Fred Grossman said: “The correlation between highest CRP levels and greatest degree of response to remestemcel-L suggests that the inflammatory component of the lung disease may trigger and be amenable to the immunomodulatory effects of treatment with remestemcel-L in patients with acute inflammatory conditions. Since recurrent hospitalization rates and mortality in COPD are associated with both high levels of CRP and progressive decline in the sixminute walk test, these results suggest that remestemcel-L could provide longer-term benefits for COPD patients with high levels of inflammation. They also provide a compelling rationale for the evaluation of remestemcel-L in the current United States Phase 3 randomized controlled trial of 300 patients with moderate to severe COVID-19 ARDS.”